Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.
| Revenue (TTM) | $52.04M |
| Gross Profit (TTM) | $-175.06M |
| EBITDA | $-294.82M |
| Operating Margin | -865.00% |
| Return on Equity | -68.50% |
| Return on Assets | -32.90% |
| Revenue/Share (TTM) | $0.26 |
| Book Value | $2.66 |
| Price-to-Book | 3.63 |
| Price-to-Sales (TTM) | 43.47 |
| EV/Revenue | 29.32 |
| EV/EBITDA | -6.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.80% |
| Shares Outstanding | $218.96M |
| Float | $184.37M |
| % Insiders | 0.94% |
| % Institutions | 95.69% |
Volatility is currently contracting
BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.
BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Kelley Allison, the Company's new SVP, Market Access and Health Policy. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to seven newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M.
BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Amy Ricca, the Company's new SVP, Head of HR. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to twelve newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
